Logo image of ALPHA.PA

Pharnext (ALPHA.PA) Stock Fundamental Analysis

EPA:ALPHA - Euronext Paris - Matif - FR001400N1P4 - Common Stock - Currency: EUR

0.0002  +0 (+100%)

Fundamental Rating

1

Overall ALPHA gets a fundamental rating of 1 out of 10. We evaluated ALPHA against 71 industry peers in the Biotechnology industry. ALPHA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ALPHA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALPHA has reported negative net income.
ALPHA had a negative operating cash flow in the past year.
ALPHA had negative earnings in each of the past 5 years.
In the past 5 years ALPHA always reported negative operating cash flow.
ALPHA.PA Yearly Net Income VS EBIT VS OCF VS FCFALPHA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

ALPHA has a Return On Assets of -627.44%. This is amonst the worse of the industry: ALPHA underperforms 98.59% of its industry peers.
Industry RankSector Rank
ROA -627.44%
ROE N/A
ROIC N/A
ROA(3y)-259.01%
ROA(5y)-189.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALPHA.PA Yearly ROA, ROE, ROICALPHA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400

1.3 Margins

ALPHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALPHA.PA Yearly Profit, Operating, Gross MarginsALPHA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -2M -4M -6M

More info and screens

0

2. Health

2.1 Basic Checks

ALPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALPHA has about the same amount of shares outstanding.
ALPHA has a worse debt/assets ratio than last year.
ALPHA.PA Yearly Shares OutstandingALPHA.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M
ALPHA.PA Yearly Total Debt VS Total AssetsALPHA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -31.74, we must say that ALPHA is in the distress zone and has some risk of bankruptcy.
ALPHA has a Altman-Z score of -31.74. This is amonst the worse of the industry: ALPHA underperforms 94.37% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -31.74
ROIC/WACCN/A
WACC6.43%
ALPHA.PA Yearly LT Debt VS Equity VS FCFALPHA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

ALPHA has a Current Ratio of 0.37. This is a bad value and indicates that ALPHA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.37, ALPHA is not doing good in the industry: 92.96% of the companies in the same industry are doing better.
A Quick Ratio of 0.37 indicates that ALPHA may have some problems paying its short term obligations.
ALPHA's Quick ratio of 0.37 is on the low side compared to the rest of the industry. ALPHA is outperformed by 92.96% of its industry peers.
Industry RankSector Rank
Current Ratio 0.37
Quick Ratio 0.37
ALPHA.PA Yearly Current Assets VS Current LiabilitesALPHA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.99% over the past year.
The Revenue for ALPHA has decreased by -99.34% in the past year. This is quite bad
ALPHA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -86.96% yearly.
EPS 1Y (TTM)99.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)-99.34%
Revenue growth 3Y-86.96%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 41.39% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALPHA will show a very strong growth in Revenue. The Revenue will grow by 93.12% on average per year.
EPS Next Y99.81%
EPS Next 2Y41.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-22.9%
Revenue Next 2Y93.12%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALPHA.PA Yearly Revenue VS EstimatesALPHA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALPHA.PA Yearly EPS VS EstimatesALPHA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100B -200B -300B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALPHA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALPHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALPHA.PA Price Earnings VS Forward Price EarningsALPHA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALPHA.PA Per share dataALPHA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5M -10M -15M -20M -25M

4.3 Compensation for Growth

A more expensive valuation may be justified as ALPHA's earnings are expected to grow with 41.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.39%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALPHA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Pharnext

EPA:ALPHA (8/26/2024, 7:00:00 PM)

0.0002

+0 (+100%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-20 2024-04-20/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.19K
Analysts86.67
Price Target12750 (6374999900%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-26278826.88
EYN/A
EPS(NY)-97850
Fwd EYN/A
FCF(TTM)-4.02
FCFYN/A
OCF(TTM)-4.01
OCFYN/A
SpS0.03
BVpS-5.15
TBVpS-5.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -627.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-259.01%
ROA(5y)-189.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20%
Cap/Sales 40%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.37
Quick Ratio 0.37
Altman-Z -31.74
F-Score3
WACC6.43%
ROIC/WACCN/A
Cap/Depr(3y)7.32%
Cap/Depr(5y)59.9%
Cap/Sales(3y)2169.88%
Cap/Sales(5y)1310.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y99.81%
EPS Next 2Y41.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-99.34%
Revenue growth 3Y-86.96%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-22.9%
Revenue Next 2Y93.12%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-98.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.65%
OCF growth 3YN/A
OCF growth 5YN/A